Drug intelligence / Profile preview

LC2

Development stage: Preclinical
Lead developer: Institute of Macromolecular Chemistry, Czech Academy of Sciences
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

LC2 is an experimental nanomedicine consisting of the chemotherapy agent cytarabine (araC) conjugated to a linear N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer via a 5-pentanoyl spacer. This polymer-drug conjugate is designed to overcome the rapid enzymatic degradation of free cytarabine, thereby improving its pharmacokinetic profile and therapeutic efficacy. In preclinical models of aggressive non-Hodgkin lymphomas, including mantle cell and Burkitt lymphoma, LC2 demonstrated sustained drug release and superior tumor growth suppression compared to free cytarabine, with the ability to delay tumor regrowth for over 40 days.

Other names: HPMA copolymer-cytarabine conjugate (5-pentanoyl spacer)HPMA-araC conjugate LC2

Targets

DNA polymerase familyDNA

Beyond the preview

Go deeper on LC2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LC2.

Explore the full profile